DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor. The company is based on prominent international research from leading universities and funded by top Norwegian tech investors.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Oslo, No
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- https://domorediagnostics.com/
- Keywords
- Cancer, Artificial intelligence, Deep learning, Diagnostics, Prognostication, Precision Medicine.
- HQ
- Oslo
Domore Diagnostics Questions
Domore Diagnostics's website is https://domorediagnostics.com/
Domore Diagnostics's LinkedIn profile is https://no.linkedin.com/company/domore-diagnostics
Domore Diagnostics has
12 employees.
View email and phone details for 12
employees at Domore Diagnostics.
Domore Diagnostics's industry is
Hospitals and Health Care
Domore Diagnostics's top competitors are
Made For Movement Norge,
Deep Bio Inc.,
Paige,
Pathai,
Norway Health Tech,
Mindpeak Gmbh,
Visiopharm,
Holocare,
Stratipath,
Dnv Imatis.
Domore Diagnostics's categories are Hospitals and Health Care
Domore Diagnostics's founding year is 2021
